CSBR insider transaction filings
CHAMPIONS ONCOLOGY, INC. — 28 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-01-30. Screen CSBR transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for CSBR between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — CHAMPIONS ONCOLOGY, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-01-30 | 4 | Brainin Robert Lawrence — CEO, Director | Grant/award (A): 225,000 (derivative) @ $7.80 · Grant/award (A): 62,500 (derivative) @ $7.80 · Grant/award (A): 62,500 (derivative) @ $7.80 · Grant/award (A): 150,000 (derivative) @ $7.80 · Grant/award (A): 100,000 (derivative) @ $7.80 · Grant/award (A): 100,000 (derivative) @ $7.80 | EDGAR |
| 2026-01-30 | 4 | Brainin Robert Lawrence — Director | Grant/award (A): 9,901 (derivative) @ $10.10 · Grant/award (A): 14,130 (derivative) @ $7 · Grant/award (A): 19,070 (derivative) @ $5.51 · Grant/award (A): 23,030 (derivative) @ $4.64 | EDGAR |
| 2025-11-07 | 4 | Breitfeld Philip P. — Director | Grant/award (A): 13,790 (derivative) @ $6.80 | EDGAR |
| 2025-11-07 | 4 | Mendelson Daniel Newman — Director | Grant/award (A): 13,790 (derivative) @ $6.80 | EDGAR |
| 2025-11-07 | 4 | SIDRANSKY DAVID — Director | Grant/award (A): 21,216 (derivative) @ $6.80 | EDGAR |
| 2025-11-07 | 4 | ACKERMAN JOEL — Director | Grant/award (A): 21,216 (derivative) @ $6.80 | EDGAR |
| 2025-11-07 | 4 | TOBIN SCOTT R — Director, 10% owner | Grant/award (A): 25,460 (derivative) @ $6.80 | EDGAR |
| 2025-11-06 | 4 | ACKERMAN JOEL — Director | Option exercise (M): 94,405 @ $2.10 · Option exercise (M): 94,405 (derivative) @ $2.10 | EDGAR |
| 2025-04-02 | 4 | Breitfeld Philip P. — Director | Other (J): 4,150 @ $0 | EDGAR |
| 2024-11-18 | 4 | Breitfeld Philip P. — Director | Grant/award (A): 18,715 (derivative) @ $4.64 | EDGAR |
| 2024-11-18 | 4 | Mendelson Daniel Newman — Director | Grant/award (A): 21,590 (derivative) @ $4.64 | EDGAR |
| 2024-11-18 | 4 | SIDRANSKY DAVID — Director | Grant/award (A): 21,880 (derivative) @ $4.64 | EDGAR |
| 2024-11-18 | 4 | ACKERMAN JOEL — Director | Grant/award (A): 43,190 (derivative) @ $4.64 | EDGAR |
| 2024-11-18 | 4 | TOBIN SCOTT R — Director, 10% owner | Grant/award (A): 34,550 (derivative) @ $4.64 | EDGAR |
| 2024-11-01 | 4 | ACKERMAN JOEL — Director | Option exercise (M): 88,470 @ $2.10 · Option exercise (M): 16,667 @ $5.43 · Option exercise (M): 88,470 (derivative) @ $2.10 · Option exercise (M): 16,667 (derivative) @ $5.43 | EDGAR |
| 2024-04-01 | 4 | Davis Brady — President | Grant/award (A): 135,000 (derivative) @ $6.50 · Grant/award (A): 7,500 (derivative) @ $6.50 · Grant/award (A): 68,000 (derivative) @ $6.50 | EDGAR |
| 2024-01-16 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 1,000 @ $6.50 | EDGAR |
| 2024-01-12 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 2,000 @ $6.27 | EDGAR |
| 2024-01-11 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 2,944 @ $6.31 | EDGAR |
| 2024-01-10 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 3,000 @ $6.25 | EDGAR |
| 2024-01-09 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 1,000 @ $6.15 | EDGAR |
| 2024-01-08 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 2,000 @ $6.09 | EDGAR |
| 2024-01-08 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 3,000 @ $6.12 | EDGAR |
| 2024-01-05 | 4 | ACKERMAN JOEL — Director | Option exercise (M): 114,552 @ $2.10 · Option exercise (M): 100,000 (derivative) @ $2.10 · Option exercise (M): 14,552 (derivative) @ $2.10 | EDGAR |
| 2024-01-04 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 500 @ $5.83 | EDGAR |
| 2023-12-26 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 2,500 @ $4.92 | EDGAR |
| 2023-12-21 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 2,100 @ $4.82 | EDGAR |
| 2023-12-20 | 4 | Mendelson Daniel Newman — Director | Purchase (P): 5,000 @ $4.75 | EDGAR |
Recent 8-K events — CHAMPIONS ONCOLOGY, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-09-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-21 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CSBR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →